Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Debt to Equity Ratio : -0.1232 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1232 |
| March 31, 2026 | -0.2871 |
| December 31, 2025 | -0.1111 |
| September 30, 2025 | -0.34 |
| June 30, 2025 | 3.073 |
| March 31, 2025 | 0.3404 |
| December 31, 2024 | -0.2985 |
| September 30, 2024 | 0.411 |
| June 30, 2024 | 0.1615 |
| March 31, 2024 | 0.1971 |
| December 31, 2023 | 0.1121 |
| September 30, 2023 | 0.0724 |
| June 30, 2023 | 0.0649 |
| March 31, 2023 | 0.0765 |
| September 30, 2022 | 0.0459 |
| June 30, 2022 | 0.0516 |
| March 31, 2022 | 0.0899 |
| December 31, 2021 | 0.087 |
| September 30, 2021 | 0.0627 |
| June 30, 2021 | 0.065 |
| March 31, 2021 | 0.0763 |
| Date | Value |
|---|---|
| December 31, 2020 | 0.2578 |
| September 30, 2020 | 0.2439 |
| June 30, 2020 | 0.1917 |
| March 31, 2020 | 0.1784 |
| December 31, 2019 | 0.1925 |
| September 30, 2019 | 0.0417 |
| June 30, 2019 | 0.0332 |
| March 31, 2019 | 0.0366 |
| December 31, 2018 | 0.5022 |
| September 30, 2018 | 0.2704 |
| June 30, 2018 | 0.2885 |
| March 31, 2018 | 0.2482 |
| December 31, 2017 | 0.5671 |
| September 30, 2017 | 0.3232 |
| June 30, 2017 | 0.4692 |
| March 31, 2017 | 0.2721 |
| December 31, 2016 | 0.0519 |
| September 30, 2016 | 0.0303 |
| June 30, 2016 | 0.505 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.0813 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Perspective Therapeutics, Inc. | 0.0122 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 29.44M |
| Total Liabilities (Quarterly) | 50.74M |
| Shareholders Equity (Quarterly) | -21.30M |
| Current Ratio | 1.997 |
| Net Debt Paydown Yield | 0.09% |